The choice of treatment according to *in vitro* drug response testing was developed for chronic lymphocytic leukemia (CLL) as the Differential Staining Cytotoxicity assay.^[@bib1]^ This demonstrated that fludarabine-test-resistant patients treated with fludarabine had a poorer response rate and worse median survival than fludarabine-test-sensitive patients.^[@bib2]^ A simplified method, the tumor response to anti-neoplastic compounds (TRAC) assay, was developed and its value documented in CLL patients.^[@bib3]^

We report the largest study in patients entered into a randomized trial, in three contexts: As a randomized variable in nonresponders and relapsed patients to assess its value in the choice of second-line therapy.Assessing *in vitro* sensitivity to therapy received, as a prognostic variable after second-line treatment.At study entry, to ascertain whether the *in vitro* sensitivity to treatment received could predict outcome, and to assess correlation with other prognostic factors.

The LRF CLL4 trial was a multicenter study including 777 CLL patients requiring treatment, randomized from 1999--2004 to receive chlorambucil, or fludarabine alone or with cyclophosphamide. Response rates, progression-free survival (PFS), overall survival (OS), and the prognostic impact of clinical and biological variables, have been published.^[@bib4],\ [@bib5]^ A second randomization (2000--2008) was incorporated for patients who were nonresponders, progressed while on first-line treatment, or relapsed within a year of remission. The trial was approved by a UK multicenter research ethics committee.

The TRAC assay was performed on blood samples. At trial entry, the result was not available to patients or physicians. The second randomization, using a new sample, was between 'TRAC-assay-guided\' and 'protocol-guided\' therapy. Randomization was balanced with respect to age, gender, disease status and planned treatment. Before second randomization, physicians specified what treatment they planned to give. TRAC assay reports were only sent to the physician for patients allocated to assay-guided therapy. TRAC methodology was previously described.^[@bib3]^ Drugs tested were chlorambucil, cyclophosphamide (mafosfamide *in vitro*), methyl-prednisolone, prednisolone, vincristine, doxorubicin, mitoxantrone, cladribine, fludarabine and pentostatin; and the drug concentrations lethal for 90% of cells (LC~90~s) were determined. The report sent to doctors showed drug sensitivities as a drug sensitivity index---a percentage rank of LC~90~s whereby 0% indicated the most resistant patient and 90% indicated very sensitive.^[@bib3]^ For analysis, trial entry LC~90~ results were compared with response. Cutoffs were determined for sensitive, intermediate and resistant. For drug combinations, all drugs needed to show resistance *in vitro* for the combination to be considered TRAC-resistant. For TRAC-sensitivity, at least one drug needed to show *in vitro* sensitivity. Patient response was assessed using the National Cancer Institute criteria. PFS was defined as the time from first randomization to relapse, progression or death. OS from randomization was the primary outcome. *χ*^2^ was used for testing associations between categorical variables. Analyses of outcome used Kaplan--Meier curves and log-rank comparisons between groups. Cox regression was used for multivariate analysis. The follow-up was up to 31st October 2010 (median follow-up from trial entry was 7 years 6 months; from second randomization 5 years 9 months). *P*-values were two-sided.

\(1\) At second randomization, 84 patients were allocated to protocol-guided and 84 patients to TRAC-assay-guided treatment. Most (73%) had initially received chlorambucil; 40% were nonresponders and 60% had relapsed. There were no significant differences between the two groups regarding patient/disease characteristics ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Fifty-two percent of physicians planned to give fludarabine as second-line treatment. The proportion of patients who did not receive the planned treatment did not differ significantly between the planned treatments (fludarabine 25%, cyclophosphamide, doxorubicin, vincristine and prednisolone 47%, fludarabine with cyclophosphamide±/−rituximab or mitoxantrone 30%). As expected, fewer TRAC-assay-guided patients received their planned treatment compared with protocol-guided (51 vs 83%, *P*\<0.0001). In the protocol-guided arm there was no difference in the proportion receiving their planned treatment by TRAC assay result (10/13 (77%) TRAC-resistant vs 51/60 (85%) TRAC nonresistant, *P*=0.5). In the TRAC-assay-guided arm 0/10 (0%) of the TRAC-resistant patients received their planned treatment compared with 41/66 (62%) TRAC nonresistant (*P*=0.0002) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). This suggests that the report, when available, was used by the physicians to alter the planned treatment when drug resistance was indicated.

There were no significant differences between assay-guided vs protocol-guided in response rate ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) or OS ([Figure 1a](#fig1){ref-type="fig"}). However, survival at 1 year was better (*P*=0.04). Results were not altered if stratified by age, stage, gender or risk group.^[@bib5]^ Within the TRAC-resistant subgroup there was no significant difference in OS between the randomized arms (odds ratio=1.04; 95% confidence interval: 0.72--1.49; *P*=0.8).

\(2\) No patient in the TRAC-assay-guided arm received a treatment to which they were resistant, compared with 17% in the protocol-guided arm (*P*=0.0002). Patients with greater *in vitro* sensitivity to the given treatment were more likely to respond (sensitive 57/68 (84%), intermediate 39/55 (71%), resistant 5/10 (50%)); (*P*(trend)=0.01), independently of the randomized arm. There was no significant difference in survival from second randomization by TRAC assay (sensitive/intermediate/resistant) to the given treatment, *P*(trend)=0.4 ([Figure 1b](#fig1){ref-type="fig"}); however, the 13 resistant patients appeared to fare worse than the others, odds ratio=1.75 (95% confidence interval: 0.82--3.72), *P*=0.2.

\(3\) At trial entry, the TRAC assay was performed in 544/777 randomized patients, and this group was broadly representative. Higher LC~90~s for fludarabine, chlorambucil and mafosfamide were associated with 17p deletion and 11q deletion and for chlorambucil and mafosfamide, but not fludarabine, with unmutated *IGHV* mutational status ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

TRAC-assay-sensitivity was predictive of improved OS ([Figure 1c](#fig1){ref-type="fig"}). In univariate analyses, LC~90~s for fludarabine, chlorambucil and mafosfamide were statistically significant for both PFS and OS ([Table 1](#tbl1){ref-type="table"}). When the TRAC assay result was added to a multivariate OS model it was not significant (*P*=0.8). For PFS, the LC~90~ for fludarabine added independent prognostic value (*P*=0.002), though the LC~90~ for chlorambucil was of borderline significance (*P*=0.05) and for mafosfamide was nonsignificant. When including LC~90~ results for both fludarabine and chlorambucil, only the fludarabine result was significant ([Table 1](#tbl1){ref-type="table"}).

Our results suggest that *in vitro* drug sensitivity correlates with patients\' outcome. When considering all relapsed/refractory patients, there was an association between *in vivo* response and greater sensitivity by TRAC assay. PFS from second randomization was not measured, but survival at 1 year was significantly better in the TRAC-assay-guided arm---a result which is of particular interest given that no chemotherapy-only protocol has been shown to increase OS.

Several studies have investigated the *in vitro* drug sensitivity of CLL cells^[@bib2],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ and its relationship with clinical and biological parameters.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ These results suggested that *in vitro* drug sensitivity of CLL cells is independent of *IGHV* gene mutation status.^[@bib11],\ [@bib14]^ However, as expected from clinical experience, *in vitro* sensitivity to fludarabine and chlorambucil was lower in patients with *ATM/TP53* deletions^[@bib13],\ [@bib14]^ and higher in patients with low-beta-2 microglobulin, longer lymphocyte doubling-time and lack of *TP53* deletion.^[@bib12]^ The *in vitro* prednisolone sensitivity of *TP53*-deleted cases correlated with the reported *in vivo* sensitivity.^[@bib15]^ These studies reported only a small number of cases, with little information concerning the relationship between the *in vitro* and *in vivo* findings. Morabito *et al.*,^[@bib9]^ using the MTT assay, concluded that *in vitro* testing for fludarabine predicted response. Castejon\'s study,^[@bib12]^ using an *in vitro* apoptotic test in 50 patients, showed that sensitivity to fludarabine correlated with a clinical response but, unlike in our study, there was no correlation between *in vitro* sensitivity and *in vivo* response to chlorambucil.

Information on the significance of *in vitro* drug sensitivity assays in CLL is limited to a few nonrandomized studies.^[@bib2],\ [@bib3]^ The main findings were a correlation between *in vitro* and *in vivo* sensitivity to fludarabine, which translated into longer survival for the fludarabine-sensitive group,^[@bib2]^ and a lack of *in vitro* cross-resistance between fludarabine and pentostatin, suggesting that pentostatin could be a salvage drug in fludarabine-resistant patients.^[@bib3]^

The present study is the only one that analyzes the value of the *in vitro* drug assay in untreated CLL patients entered into a randomized clinical trial, and in whom clinical and biological prognostic factors were considered. *In vitro* drug resistance correlated with the presence of 17p and 11q deletion, as documented in other small studies,^[@bib13],\ [@bib14]^ but also with unmutated *IGHV* genes. The TRAC assay LC~90~(fludarabine), together with 17p and 11q deletion and *IGHV* gene mutation status was an independent variable predicting PFS. Although the TRAC assay result was associated with OS in univariate analysis, it was not significant in multivariate analysis. This might be because most relapsed and refractory patients had been treated with chlorambucil and were rescued with alternative therapies.

In summary, the TRAC assay may be of value in practice, particularly in untreated patients who are unfit for intensive regimens and for whom treatment with chlorambucil or fludarabine is planned. The use of these agents in patients with *in vitro* drug resistance predicts nonresponse. In the relapse setting, short-term survival may be improved, while further studies including new agents (for example, bendamustine, lenalidomide) in the panel of drugs tested may give additional information on the clinical value of testing. At diagnosis, the TRAC assay provided prognostic information additional to other known factors.
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![(**a**) OS from second randomization by TRAC-assay-guided (hashed line) vs protocol-guided arm (solid line). (**b**) OS by *in vitro* sensitivity to the given second-line treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line). (**c**) OS from first randomization by *in vitro* sensitivity to the randomized treatment (sensitive=solid line, intermediate=hashed line, resistant=hashed/dotted line).](leu2012209f1){#fig1}

###### Cox regression analyses for LC~90~ TRAC assay results[a](#t1-fn2){ref-type="fn"} at trial entry

  *Variable*                                                                                                                                                                        *Events*/*Patients*  *HR and 95% confidence interval*   P-*value*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ---------------------------------- -----------
  *OS*---*univariate analysis*[b](#t1-fn3){ref-type="fn"}[c](#t1-fn4){ref-type="fn"}                                                                                                                                                        
   Log~10~ LC~90~-flu                                                                                                                                                                     356/544        1.35 (1.15−1.58)                   0.0003
   Log~10~ LC~90~-chl                                                                                                                                                                     355/543        3.16 (2.25−4.44)                   \<0.0001
   Log~10~ LC~90~-maf                                                                                                                                                                     354/536        1.82 (1.25−2.65)                   0.002
                                                                                                                                                                                                                                             
  *PFS*---*univariate analysis*[b](#t1-fn3){ref-type="fn"}                                                                                                                                                                                  
   Log~10~ LC~90~-flu                                                                                                                                                                    500/ 544        1.65 (1.42−1.91)                   \<0.0001
   Log~10~ LC~90~-chl                                                                                                                                                                    499/ 543        2.48 (1.86−3.32)                   \<0.0001
   Log~10~ LC~90~-maf                                                                                                                                                                    493/ 536        1.65 (1.19−2.48)                   0.003
                                                                                                                                                                                                                                             
  *PFS*---*multivariate analysis*[e](#t1-fn6){ref-type="fn"} *Addition of LC~90~-flu to model with other known prognostic factors (excluding del17p)*[d](#t1-fn5){ref-type="fn"}                                                            
   *Treatment*                                                                                                                                                                                                                               
    Flu                                                                                                                                                                                  261/ 284        1.00                               \<0.0001
    Chl                                                                                                                                                                                                  1.30 (0.97−1.74)                    
    Flu with cyclophosphamide                                                                                                                                                                            0.53 (0.38−0.75)                    
                                                                                                                                                                                                                                             
   11q deletion                                                                                                                                                                                          1.53 (1.14−2.05)                   0.005
   β2 microglobulin ⩾4 mg/l                                                                                                                                                                              1.35 (1.06−1.74)                   0.02
   *IGHV* unmutated and/or *V3-21* usage                                                                                                                                                                 2.03 (1.54−2.68)                   \<0.0001
   Log~10~ LC~90~-flu                                                                                                                                                                                    1.50 (1.17−1.93)                   0.002

Abbreviations: chl, chlorambucil; flu, fludarabine; HR, hazard ratio; maf, mafosfamide; OS, overall survival; PFS, progression-free survival; TRAC, tumor response to anti-neoplastic compounds.

LC90 values modeled instead of TRAC categories as definitions of both TRAC resistance and PFS use response.

HR for LC~90~ results are for a unit increase.

None of the LC~90~ values retained significance in multivariate analysis for OS.

LC~90-~chl and LC~90~-maf were not significant after the inclusion of these factors and so have been removed from the model.

Multivariate analyses tested whether the TRAC assay results added value to the previously identified prognostic factors,^[@bib5]^ with models fitted both with and without the inclusion of the TRAC assay to the baseline models, and the change in deviance examined between the two models. Final model presented in table.
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